INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:IN.

$0.80
As of 05/27/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  11/12/2020
Outstanding shares:  14,641,645
Average volume:  90,819
Market cap:   $11,127,650
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   -1.51
PB ratio:   1.05
PS ratio:   41.93
Return on equity:   -275.74%
Net income %:   -3,962.54%